EGFR and cancer: Having demonstrated that the proapoptotic activity of rTBL-1 is not restricted to EGFR-expressing cancers, and given that, unlike its native counterpart, rTBL-1 does not exhibit erythro-agglutinating properties [37] that contraindicate its administration by the intralesional route, we set out to investigate whether the proapoptotic activity of rTBL-1 is capable of producing antitumor responses in CRC in vivo in a targeted delivery setting.